Skip to Content

Announcing Sakura 3 Results

Disclaimer: DaxibotulinumtoxinA for Injection is currently an investigational product and not approved by FDA. Anticipated approval in 2020.

More than 73.5% subjects in Sakura 1 and 2 achieved a two-grade improvement in glabellar lines as assessed by with the patient and the investigator at week 4 after treatment1

Back to top